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OBJECTIVE—Glucose is the major stimulus for insulin release. Time course and amount of
insulin secreted after glycemic stimulus are different between type 2 diabetes mellitus (T2DM)
patients and healthy subjects. In rodents, it was demonstrated that insulin can modulate its own
release. Previous studies in humans yielded contrasting results: Insulin was shown to have an
enhancing effect, no effect, or a suppressive effect on its own secretion. Thus, we aimed to
evaluateshort-termeffectsofhumaninsulininfusiononinsulinsecretionduringnormoglycemia
in healthy humans and T2DM subjects of both sex.
RESEARCH DESIGN AND METHODS—Hyperinsulinemic-isoglycemic clamps with
whole-body insulin-sensitivity (M) and C-peptide measurements for insulin secretion modeling
were performed in 65 insulin-sensitive (IS) subjects (45 6 1 year, BMI: 24.8 6 0.5 kg/m
2), 17
insulin-resistant(IR)subjects(4662years,28.161.3kg/m
2),and20T2DMpatients(5662years,
28.0 6 0.8 kg/m
2;H b A 1c =6 . 76 0.1%).
RESULTS—IS subjects (M =8 . 86 0.3 mg z min
21 z kg
21) had higher (P , 0.00001) whole-
body insulin sensitivity than IR subjects (M =4 . 06 0.2) and T2DM patients (M =4 . 36 0.5).
Insulin secretion proﬁles during clamp were different (P , 0.00001) among the groups, in-
creasing in IS subjects (slope: 0.56 6 0.11 pmol/min
2) but declining in IR (20.41 6 0.14) and
T2DM (20.87 6 0.12, P , 0.00002 IR and T2DM vs. IS) subjects. Insulin secretion changes
during clamp directly correlated with M (r = 0.6, P , 0.00001).
CONCLUSIONS—Insulin release during normoglycemia can be modulated by exogenous
insulininfusionanddirectlydependsonwhole-bodyinsulinsensitivity.Thus,inhighlysensitive
subjects,insulinincreasesitsownsecretion.Ontheotherhand,asuppressiveeffectofinsulinon
its own secretion occurs in IR and T2DM subjects.
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mpaired insulin secretion, as seen in
type 2 diabetes mellitus (T2DM) or
prediabetic states, results in prolonged
hyperglycemic episodes (1). Both the
time course and the amount of secreted
insulin are different in T2DM patients
compared with healthy subjects (1).
Because the b-cell not only secretes
insulin but also expresses insulin re-
ceptors to activate the insulin signal
transduction cascade (2), it might follow
that insulin has the potential to modulate
its own release, depending on the intact-
ness of the insulin signaling cascade,
which is impaired in insulin resistance
and T2DM (3).
Previous contrasting results have
shown that, in both healthy and T2DM
subjects, insulin infusion during main-
tainednormoglycemiahadnoeffect(4–6)
or had a suppressive (7–10) effect on C-
peptide release. Such contrasting results
may be partially due to the fact that, in
those previous studies (4–10), insulin
sensitivity was not assessed. However, a
mostrecentstudydescribedinsulintoen-
hance its own secretion in insulin-sensi-
tive (IS) humans (11). Thus, we aimed to
study theshort-termeffects ofaninfusion
of human insulin on insulin secretion
during normoglycemia in IS, insulin-re-
sistant (IR), and T2DM subjects.
RESEARCH DESIGN AND
METHODS—Subjects, recruited by
means of local advertising from January
2002 to March 2005, gave informed
consent to the protocols, approved by
the ethics board of the Vienna Medical
University.Allparticipantswererecruited
by means of local advertising, as pre-
viously explained in detail (12,13). An
oral glucose tolerance test was performed
in nondiabetic subjects (NDS) to conﬁrm
theirnondiabeticmetabolism(13).Atotal
of 102 humans were included (Table 1),
20 of whom had T2DM. NDS were in ex-
cellent health and in absence of any regu-
lar drug intake (12–15). Among the NDS,
24 reported to be ﬁrst-degree offspring of
patients with T2DM. T2DM subjects had
known diabetes for at least 3 years and no
clinical existence of renal, hepatic, and
cardiovascular diseases (12); their treat-
ment included metformin, sulfonylureas/
glinides, and/or a-glucosidase inhibitors.
After a 10-h overnight fast, two cath-
eters (Vasoﬁx; Braun, Melsungen, Ger-
many)wereinsertedintotheleftandright
antecubital veins for blood sampling and
infusions, respectively. For glucose mea-
surement, venous blood was drawn in an
arterializingmanner(16,17).Themeanof
three fasting plasma glucose measure-
ments was assigned as the isoglycemic
clamp goal. Whenever the goal was
,4.44 or .5.55 mmol/L, 4.44 or 5.55
mmol/L was chosen, respectively (13–
17). The hyperinsulinemic-isoglycemic
clamp was performed for 120 min in NDS
and 150 min in T2DM subjects, with a
primed continuous (40 mU min
–1 z m
–2
body surface area) infusion of regular
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ORIGINAL ARTICLEinsulin (Actrapid; NovoNordisk, Bagsvaerd,
Denmark) (12–15,17). Clamp goal was
maintained by infusing variable amounts
of a 20% D-glucose solution. The differ-
ence between fasting plasma glucose and
clamp glucose goal was on average 0.04
mmol/L in NDS but 0.82 mmol/L in
T2DM subjects. The plasma glucose coef-
ﬁcient of variation during the ﬁnal clamp
hour was 7 6 0% for NDS, 6 6 1% for
T2DM subjects, 8 6 0% for IS subjects,
and 5 6 0% for IR subjects. For measure-
ment of insulin, C-peptide, and FFA,
blood was collected in EDTA-containing
tubesatbaseline,at260min,at230min,
andimmediatelybeforetheendoftheclamp
to be centrifuged and stored at 270° C. As
previously shown (14,15), the threshold for
insulin resistance is insulin-stimulated glu-
cose utilization (M) ,5m gz min
21 z kg
21;
NDS were deﬁned as IR (M # 5.0) or IS
(M . 5.0).
All of the variables characterizing the
groups(Table1)wereassessedusingrou-
tine laboratory methods (13–17). Glu-
cose was measured by glucose oxidase
(Glucose AnalyzerII;Beckman,Fullerton,
CA) (13); plasma insulin and C-peptide
were measured by radioimmunoassays
(Linco, St. Charles, MO) (13). FFA was
measured with a microﬂuorometric assay
(WakoChemicals,Richmond,VA).Insulin
sensitivity was calculated as the mean M
during 20-min intervals of the clamp
(14,15,17). Total insulin secretion was cal-
culated from plasma C-peptide concentra-
tions by deconvolution (18). Sensitivity of
the b-cell to glucose was determined by
dividing insulin secretion by correspond-
ing plasma glucose concentrations. The
gradients of insulin secretion in relation to
and of plasma glucose during clamp were
calculated as the slope of the linear ﬁto fi t s
values over time.
Normal distribution was tested by
applying the Kolmogorov–Smirnov test.
Differences between groups were ana-
lyzed by ANOVA after a two-sided Bon-
ferroni post hoc test. Pearson’sp r o d u c t
moment correlation was used to estimate
linear relationships between variables.
A stepwise backward regression was per-
formed. Data are presented as means 6
SE; P , 0.05 was considered statisti-
cally signiﬁcant (SPSS 13.0; SPSS Inc.,
Chicago, IL).
RESULTS—Body mass was similar in
IR and T2DM subjects but smaller in IS
subjects (Table 1). T2DM subjects were
olderwithhighercreatinine,uricacid,tri-
glycerides, total/LDL cholesterol, and ala-
nine aminotransaminase. Baseline plasma
insulin was similar in IR and T2DM sub-
jects but lower in IS subjects. Plasma in-
sulininthethreegroupswassimilaratthe
end of the clamp (Fig. 1F). C-peptide was
differentatbaselineinallthreegroupsbut
similar at the end of the test (Fig. 1G).
Insulin sensitivity (M) wasapproximately
twofold higher in the IS group than in
both IR and T2DM groups (Table 1).
Basal insulin secretion from C-peptide
wasthehighestinT2DM subjects(+112%
vs. IS: P , 0.00001; +34% vs. IR: P ,
0.02; IR vs. IS +58%, P , 0.002; Fig. 1A).
During the ﬁnal 60 min, insulin secretion
(C-peptide secretion [CPS]) became com-
parableinallgroups.TheslopeofCPSwas
positive in IS subjects but negative in IR
and T2DM subjects (Fig. 1Ai n s e t ). Be-
causeofthemorepronouncedglucosede-
cline in T2DM subjects, we adjusted
insulin secretion for plasma glucose by di-
viding CPS by the corresponding plasma
Table 1—Baseline anthropometric and clinical characteristics (at fasting), and basal and end-clamp results in IS, IR, and T2DM subjects
IS IR T2DM P (ANOVA)
Baseline anthropometric and clinical characteristics
N 65 17 20 —
Sex (% female/% male) 65/35 65/35 40/60 0.134
Body weight (kg) 72.7 6 1.5 81.6 6 4.5 82.5 6 2.6# 0.004
BMI (kg/m
2) 24.8 6 0.5 28.1 6 1.3* 28.0 6 0.8# 0.001
Age (years) 45 6 14 6 6 25 6 6 2#§ ,0.001
Serum creatinine (mg/dL) 0.82 6 0.02 0.83 6 0.04 0.94 6 0.04# 0.009
Serum uric acid (mg/dL) 4.8 6 0.2 4.8 6 0.3 5.8 6 0.3#§ 0.033
HbA1c (%) 5.4 6 0.0 5.6 6 0.1 6.7 6 0.1#§ ,0.001
Serum triglycerides (mg/dL) 91 6 59 6 6 16 166 6 12#§ ,0.001
Serum total cholesterol (mg/dL) 207 6 52 0 7 6 10 273 6 16#§ ,0.001
Serum HDL cholesterol (mg/dL) 60 6 25 4 6 35 4 6 20 . 1 0 6
Serum LDL cholesterol (mg/dL) 129 6 41 3 4 6 10 186 6 15#§ ,0.001
Serum ASAT (GOT) (units/L) 24 6 12 5 6 22 3 6 10 . 6 7 3
Serum ALAT (GPT) (units/L) 22 6 12 8 6 53 0 6 2# 0.012
Plasma glucose (mmol/L) 4.9 6 0.1 5.0 6 0.1 7.5 6 0.3#§ ,0.001
Hyperinsulinemic-isoglycemic clamp
Plasma glucose slope (mg z dL
21 z min
21) 20.01 6 0.01 20.05 6 0.01 20.22 6 0.04#§ ,0.001
Plasma insulin (nmol/L)
Basal 0.05 6 0.00 0.10 6 0.03* 0.10 6 0.02# 0.001
Clamp-end 0.50 6 0.02 0.55 6 0.04 0.54 6 0.02 0.204
Plasma C-peptide (nmol/L)
Basal 0.49 6 0.03 0.75 6 0.09* 1.04 6 0.07#§ ,0.001
Clamp-end 0.68 6 0.05 0.65 6 0.07 0.59 6 0.04 0.594
M (mg glucose z min
21 z kg
21)
ﬁnal 20-min interval 8.8 6 0.3 4.0 6 0.2* 4.3 6 0.5# ,0.001
Data are means 6 SE. Signiﬁcant P values from ANOVA are presented in boldface type. ALAT, alanine aminotransaminase; ASAT, aspartate aminotransaminase;
M,c l a m pM-value. ANOVA after a Bonferroni post hoc test: *P , 0.05 IR vs. IS. #P , 0.05 T2DM vs. IS. §P , 0.05 T2DM vs. IR.
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Insulin secretion during insulin infusionglucose concentration (17). This b-cell
sensitivity to glucose (Fig. 1B) was similar
in IR and IS subjects at the end of the test
butlower inT2DM subjects.Theslopesof
b-cell sensitivity to glucose (Fig. 1B inset)
were also positive in IS subjects but nega-
tive in IR and T2DM subjects.
All of the secretion indices correlated
directlywithM:CPSattheendoftheclamp
(in % of basal; r =0 . 5 9 ,P , 0.0001; Fig.
1C),the absolute CPS (r =0 . 2 0 ,P , 0.05),
and the b-cell sensitivity (r = 0.23, P =
0.02).Incontrast,M wasnegativelyrelated
to basal CPS (r = 20.530, P , 0.00001)
andwhenadjusted to glucose (r=20.408,
P , 0.0001).
FFAs were comparable at fasting, but
after insulin-mediated release inhibition,
they were higher in IR subjects than in IS
and T2DM subjects (Fig. 1D). Plasma glu-
coseatfastingwasgreaterby;2.5mmol/L
in T2DM subjects, which is also reﬂected
by the glucose slope differences (Table 1);
thus,thestudydesignimposedagoalinthe
T2DM subjects greater by ;0.6 mmol/L
(Fig. 1E).
Predictors of glucose-adjusted
insulin secretion
Age, BMI, whole-body insulin sensitivity
(M), clamp-end plasma insulin concentra-
tion, clamp glucose slope, basal glucose-
adjusted insulin secretion, basal plasma
concentrations of insulin and glucose, and
group afﬁliation factors (1 = IS, 2 = IR, 3 =
T2DM) were included.
T h es t e p w i s eb a c k w a r dr e g r e s s i o n( r
2 =
0.401) in all participants revealed M (b =
0.021 6 0.005, P , 0.00006) to be the
strongest predictor of b-cell sensitivity,
whereas clamp-end insulin concentration
(b = 0.266 6 0.098, P , 0.01) and group
afﬁliation (b = 20.051 6 0.020, P , 0.02)
werealsopredictors,althoughmuchweaker.
CONCLUSIONS—Insulin secretion
was investigated during an infusion of
humaninsulintoincrease insulin to post-
prandial-like concentrations, while main-
taining normoglycemia (13,17), in a large
cohort (n=102)ofIS,IR,andT2DMsub-
jects. The major result of this study isthat
insulin infusion leads to an increase in in-
sulin secretion in IS humans, whereas a
decrease was observed in IR subjects,
regardless of the presence of T2DM. To
the best of our knowledge, this has never
been described before as a whole. In addi-
tion, the magnitude of the increase in in-
sulin secretion during insulin infusion
directlydependson,andispredominantly
predicted by, individual whole-body
Figure 1—The clamp time course of (A) insulin secretion with its slope (inset) and of (B) insulin
secretion adjustedto prevailing plasmaglucose concentrations withits slope(inset).C:Pearson’s
product moment correlation. The correlation of insulin secretion change (in %) at the end of the
clamp compared with baseline with ﬁnal 20-min M. The clamp time course of FFA (D), plasma
glucose (E),insulin(F), and C-peptide (G)i nI S( O, n =6 5) ,I R( ●, n = 17), and T2DM (△, n =
20) subjects. Data are presented as means 6 SE. ANOVA after a Bonferroni post hoc test: *P ,
0.05 IR vs. IS; #P , 0.05 T2DM vs. IS; §P , 0.05 T2DM vs. IR.
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Anderwald and Associatesinsulin sensitivity, which again is a novel
ﬁnding.
Insulin release
C-peptide concentration was exploited to
estimate insulin secretion (1,18,19), be-
cause having infused human insulin, the
assay would be unable to discriminate en-
dogenous from exogenous insulin and
modeling-based analysis is the only possi-
ble way to noninvasively determine CPS.
Because glucose levels between fasting
and clamp end were different in T2DM,
we adjusted insulin release for the prevail-
ingglucoselevelstofurtherproveourﬁnd-
ings. Basal insulin secretion adjusted to
glucose was negatively related to M, indi-
cating that the b-cell sensitivity to glucose
at fasting aims to compensate for the de-
cline in insulin sensitivity (1). However,
duringclamp,thisassociationbecamepos-
itive, indicating that exogenous insulin ad-
ministration has the potential to modulate
both insulin secretion and b-cell glucose
sensitivity, regardless of glycemia. In con-
trast, insulin secretion at basal was nega-
tively associated with M, which has been
shown repeatedly (20). It should be added
that if insulin were to exert its effect on
b-cell function through the insulin recep-
tor mechanism, then this might be saturat-
able. In this case, it is possible the IR and
T2DM groups are already at the maximum
forthispathway,andthiscouldexplainthe
positive association only in the IS group.
Our ﬁndings are not in contrast with
previous studies reporting enhancement
(11), no effect (4–6), or suppression (7–
10) by insulin infusion on C-peptide re-
lease.Intheinvestigationsfromthe1970s
and 1980s (4–10), insulin sensitivity was
not measured; thus, an IR state of those
study participants cannot be ruled out.
The most recent study byBouche etal.
(11) did measure both insulin sensitivity
and insulin/C-peptide release during insu-
lin infusion using a sophisticated study
protocol with B28-Asp insulin analog and
stable isotope labeled C-peptide. They
found in highly IS humans (M of 10–11
mg z min
21 z kg
21) that insulin increases
its own secretion by ;40% (11), which is
completely in line with our ﬁndings. De-
spite use of a different but well-established
approach, our study furthers this observa-
tion because we included IR subjects, in
whom insulin-mediated decline on insulin
release was clearly demonstrated. Bouche
et al. (11) also found a slightly but signiﬁ-
cantly higher C-peptide clearance by ;7%
i nt h ep r e s e n c eo fh yperinsulinemia in
highly IS subjects, whereas we found no
differenceinC-peptidedegradationincon-
trol, obese, and diabetic subjects without
renal damage (21). Nevertheless, when
assuming a slightly higher C-peptide clear-
ance, measured C-peptide concentrations
would be a bit more lowered, so that our
calculated insulin secretion pattern (Fig. 1)
would be even more pronounced in the IS
subjects. Taken together, a slight variation
in C-peptide clearance and thus CPS dur-
inghyperinsulinemiacannotbecompletely
ruled out, but its effect seems small so that
changes of this study’s main outcome are
unlikely.
As a clinical implication of our study,
it can be afﬁrmed that correcting elevated
circulating glucose concentrations by in-
sulinadministrationinT2DMorcritically
ill patients seems not to bear any risk,
because hyperglycemia per se induces
insulin resistance as the result of gluco-
toxicity(3)andinsulindecreasesitssecre-
tion in insulin resistance. On the other
hand, if insulin sensitivity increases dur-
ing rapid weight loss or recovery from
severe illnesses, uncontrolled insulin ad-
ministration may be risky.
The mechanism for the insulin-
stimulated CPS seems difﬁcult to ex-
plain: The pancreatic b-cell not only
secretes insulin but also expresses in-
sulin receptors to activate the insulin
signal transduction cascade (2). By
knocking out the b-cell insulin receptor
or downstream proteinsoftheinsulinsig-
naling cascade in rodents, Kulkarni et al.
(22–24) demonstrated a marked defect in
insulin expression and secretion resem-
bling that of T2DM. Fromthisit might fol-
low that insulin has the potential to
modulateits own release,possibly through
its own signaling cascade. The insulin sig-
naling cascade is impaired in insulin resis-
tanceandT2DM(3);thus,theabilityofthe
b-cell to respond to hyperinsulinemia
(autocrine or paracrine effect) might be
blunted. Circulating FFAs play a crucial
role in IR induction (3). Thus, we thought
that FFA may affect CPS. However, circu-
lating FFAs were similar in IS and T2DM
groups; thus, FFAs seem rather not to be
involved in insulin-mediated CPS.
Study limitations
Serum potassium, which may also affect
insulin release, was not measured during
the clamp test. In addition, the patients
with T2DM were receiving antihypergly-
cemic agents, which were stopped 1–3
days before the clamp test (12). However,
some prolonged effects on CPS, pre-
dominantly caused by sulfonylurea
metabolites in T2DM, cannot be ruled
out, but they would rather increase CPS.
Because T2DM subjects had the lowest
CPS during insulin infusion compared
with NDS, an even more pronounced re-
duction in T2DM subjects might be pos-
sible. The different clamp-test glycemia
between T2DM subjects and NDS once
again presents the difﬁculty in comparing
humans with and without T2DM during
an isoglycemic clamp test, because CPS
would be higher when glucose increases
o v e rb a s a li nN D S .T h u s ,w es o u g h tt o
deﬁne near-isoglycemia for NDS and
took into account the expected glucose
decrease in T2DM subjects. Nevertheless,
under our study setting, a b-cell rest dur-
ing the clamp cannot be excluded for the
T2DM and IR participants. However, it
should be added that, after withdrawal
of antidiabetic medication in our subjects
with mild T2DM, fasting glucose concen-
trations with 7.5 mmol/L (Table 1) were
still notthatincreasedtoinducediminished
insulin release (i.e., b- c e l lr e s t ) ,w h i c h
would occur at .9 mmol/L fasting glu-
cose (25).
Inaddition,ageandbodymassdiffer-
ences among groups became evident.
However, diabetes development is favored
by elevated body weight, which in turn
downgrades whole-body insulin sensitivity
(3,14). Therefore, body mass-matched
groups of T2DM subjects and NDS are dif-
ﬁculttorecruit.However,theIRgrouphada
BMI comparable to that in the T2DM group
to allow for comparison between diabetic
subjects and NDS. Of note, regression anal-
ysis did not detect any effect from these
anthropometric characteristics, so the differ-
ences in age and body mass seem not to
affect insulin secretion in our population.
Another point may be the differences
between NDS and T2DM subjects in
fasting glucose concentrations. However,
the T2DM subjects were not receiving
regular insulin, and antihyperglycemic
drugs were withdrawn. Thus, it seems that
thestudysettingbearsthisdisadvantage,but
this cannot be easily overcome, because
(fasting) hyperglycemia is the given ma-
jor characteristic of the studied disease.
Conclusion
Insulin increases its own secretion in IS
subjects, whereas in IR subjects, includ-
ing those with T2DM, insulin exerts
suppressive effects on its own release.
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